Chandra Lovejoy

Chandra joined Erasca as senior vice president of regulatory affairs with 20 years of global drug development experience, ranging from pre-investigational new drug activities through new drug application (NDA) submission and post-approval. Her career has focused on oncology and has included drug/diagnostic development and novel trial designs and endpoints. She joined Erasca from G1 Therapeutics, where she was vice president of regulatory affairs and led health authority negotiations resulting in US Food and Drug Administration (FDA) breakthrough therapy designation and NDA approval for CoselaTM. Chandra previously served as senior vice president, global regulatory affairs and head of quality at Sierra Oncology and vice president of global regulatory affairs at Endocyte. Earlier in her career, she held roles of increasing responsibility at Genentech, including as regulatory lead for Avastin®, and previously was at Avi BioPharma.

Chandra has an M.S. in regulatory affairs from San Diego State University and a B.S. in organizational behavior from the University of San Francisco.